California is currently home to 5595 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia
Recruiting
The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/27/2024
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Anarthria, Dysarthria, Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked in Syndrome, Muscular Dystrophies
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
Recruiting
The objective of this study is to determine the safety and effectiveness of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in patients with moderate-severe central vision loss due to late-stage age-related macular degeneration (AMD).
Gender:
ALL
Ages:
65 years and above
Trial Updated:
11/27/2024
Locations: Loma Linda University, Loma Linda, California
Conditions: Age-Related Macular Degeneration, Geographic Atrophy
Addressing Diabetes by Elevating Access to Nutrition
Recruiting
The goal of ADELANTE is to determine whether a multi-level intervention to improve household food insecurity and glycemic control is effective for Latino patients with diabetes. Specifically, ADELANTE aims to 1. determine whether weekly household food delivery plus an intensive lifestyle intervention is more effective than usual care for improving glycemic control (HbA1c) at 6 months, 2. examine the effects of the multi-level intervention on = household food insecurity, dietary behaviors, and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: La Clínica Monument, Concord, California
Conditions: Diabetes, Obesity, Lifestyle, Healthy
Distal Ischemic Stroke Treatment With Adjustable Low-profile Stentriever
Recruiting
The objective of the DISTALS Study is to evaluate the safety and effectiveness of the Tigertriever 13 Revascularization Device in restoring blood flow in the neurovasculature by removing thrombus in patients presenting within 24 hours of onset with an ischemic stroke with disabling neurological deficits due to a primary distal vessel occlusion (DVO), as compared to medical management.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
11/27/2024
Locations: Providence Health, Fullerton, California
Conditions: Ischemic Stroke, Neovascularization
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
Recruiting
A study to evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon liver biopsy information among patients who received or are receiving TURALIO™ (pexidartinib) and experience hepatotoxicity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: Kamalesh K Sankhala MD INC, Santa Monica, California
Conditions: Hepatotoxicity, Tenosynovial Giant Cell Tumor
Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma
Recruiting
This phase I trial studies the side effects and best dose of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain in treating patients with MPP2+ glioblastoma that has come back (recurrent) or that is growing, spreading, or getting worse (progressive). Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma
The GAstric Precancerous Conditions Study
Recruiting
Gastric cancer afflicts 27,000 Americans annually and carries a dismal prognosis. One reason for poor outcomes is late diagnosis, as the majority of gastric cancers in the United States are diagnosed at a relatively advanced stage where curative resection is unlikely. Gastric precursors (such as atrophic gastritis and intestinal metaplasia) are precancerous changes to the stomach mucosa which increases risk for subsequent gastric cancer. The Gastric Precancerous Conditions Study (GAPS) is an ob... Read More
Gender:
ALL
Ages:
Between 35 years and 84 years
Trial Updated:
11/27/2024
Locations: Stanford University, Stanford, California
Conditions: Gastric Cancer, Intestinal Metaplasia of Gastric Mucosa, Helicobacter Pylori Infection, Atrophic Gastritis
Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
Recruiting
Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in the gene for type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening subjects with RDEB to evaluate characteristics of the subjects and their cells in order to develop new strategies of therapy and determine whether subjects could be candidates for treatment studies.
Gender:
ALL
Ages:
All
Trial Updated:
11/27/2024
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Epidermolysis Bullosa Dystrophica
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
Recruiting
This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium labelled prostate-specific membrane antigen radioligand therapy (LuPSMA RLT) at the West Los Angeles VA (WLA-VA) will be imaged with a baseline F-18 fluorodeoxyglucose positron emission tomography/computed tomography 18F-FDG PET/CT and a 18F-DCFPyL PET/CT (18F-DCFPyL (2-(3-{1-carboxy-5-\[(6-18F-fluoro-pyridine-3-carbonyl)-amino\]-pentyl}-ureido... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: VA Greater Los Angeles Healthcare System, Los Angeles, California
Conditions: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Metastatic Prostate Cancer, Male Urogenital Diseases, Prostatic Diseases, Urogenital Diseases, Male, Genital Diseases, Male, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Genital Neoplasms, Male
Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries
Recruiting
The goal of this clinical trial is to learn if targeted medical therapy will improve symptoms and quality of life in patients with angina and non-obstructive coronary arteries compared to placebo, after the underlying cause of the chest pain has been ascertained by coronary function testing. Participants will be treated with either medications that target the underlying cause of their chest pain or placebo for 4 weeks after a drug titration phase of 1-3 weeks. They will be asked to complete a s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Stanford Hospital, Palo Alto, California
Conditions: Angina Pectoris, Microvascular Angina, Vasospastic Angina, Myocardial Bridge of Coronary Artery
Treatment to Lift Facial Lax Skin and Improve Facial Wrinkles Using Precise and Lift Applicators
Recruiting
Open-label, non-randomized single-arm prospective, multi-center, self-controlled clinical study with masked evaluation.
Gender:
ALL
Ages:
Between 35 years and 80 years
Trial Updated:
11/26/2024
Locations: Costal Skin & Eye Institute, La Mesa, California
Conditions: Lax Skin
A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Recruiting
This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of DCC-3116 in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of DCC-3116 with other anticancer agents.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: GIST